Compounds Studied in Immune and Thymic Research

BPC-157 (also written as Body Protection Compound 157) is a synthetic pentadecapeptide fragment derived from a sequence found in human gastric juice. It is supplied as a lyophilised solid and is handled in laboratory work as a research-grade peptide. Its formal sequence and molecular weight are not stated in the evidence reviewed here. In the same research area, BPC-157 has been examined in a randomised, double-blind, placebo-controlled pilot trial in patients undergoing arthroscopic rotator cuff repair, where it was administered by subcutaneous injection daily for 90 days following surgery [7].

The work surveyed below centres on inflammatory signalling, mitochondrial turnover, and the incretin receptor family, with several compounds studied in models of immune activation, tissue repair, and metabolic disease.

Research Studies

BPC-157 and tendon healing after rotator cuff repair

A randomised, double-blind, placebo-controlled pilot trial enrolled twenty patients undergoing arthroscopic rotator cuff repair and assigned them to BPC-157 or saline placebo, with self-administered subcutaneous injections daily for 90 days after surgery. The study was designed to assess tendon healing and functional recovery. The evidence notes that BPC-157 had shown regenerative and anti-inflammatory effects in preclinical animal models of musculoskeletal injury but had not previously been studied in formal human clinical trials [7].

Semaglutide and cardiometabolic risk after gestational diabetes

An effectiveness-implementation Hybrid Type 1 randomised clinical trial evaluated immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus. A total of 226 postpartum individuals were randomised 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase, with the primary effectiveness outcome being development of metabolic syndrome at 6 months postpartum. Participants then entered a 6-month maintenance phase in which continuation, discontinuation, or initiation of semaglutide reflected patient and clinician decisions [2].

Semaglutide and cardiometabolic profile in schizophrenia with metabolic syndrome

A multicentre, double-blind, placebo-controlled randomised trial evaluated adjunctive oral semaglutide 3 mg once daily added to treatment as usual in patients with schizophrenia on second-generation antipsychotics. The trial assessed whether the addition reduced 10-year cardiovascular risk by QRISK3 and improved insulin resistance, lipids, weight, and metabolic biomarkers over 24 weeks compared with placebo, while confirming psychiatric safety and tolerability [9].

Nicotinamide and retinal protection in primary open-angle glaucoma

The NADIR trial is testing whether high-dose nicotinamide, a vitamin B3 supplement, protects retinal nerve cells in adults with primary open-angle glaucoma already receiving standard eye drops or laser treatment. Participants were randomly assigned to nicotinamide tablets by mouth, starting at 1.5 grams per day, or to standard therapy alone. The main question is whether adding nicotinamide slows the rate of thinning of the inner retinal nerve cell layer, measured by a non-invasive eye scan, over 12 months [3].

Nicotinamide riboside and walking distance in peripheral artery disease

The NICE-PAD II trial randomised 250 participants with peripheral artery disease aged 50 and older to nicotinamide riboside or placebo for six months. The primary outcome was change in six-minute walk distance at six-month follow-up. Secondary outcomes included the Walking Impairment Questionnaire distance score, PROMIS Mobility score, and calf muscle perfusion measured by magnetic resonance arterial spin labelling [11].

Tirzepatide and preoperative optimisation before gastric bypass

A study compared three preoperative strategies before one anastomosis gastric bypass for severe obesity: tirzepatide for 60 days, a ketogenic diet for 4 weeks, or standard care. The main goal was to determine which approach produced the best weight loss one year after surgery, with additional evaluation of safety, surgical outcomes, and improvement of obesity-related conditions such as diabetes, high blood pressure, and sleep apnea [5].

GLP-1/GIP receptor agonists and obesity-related HFpEF

GLIDE-HF is a prospective, single-centre, non-interventional observational cohort registry conducted within routine outpatient heart failure care in Poland. It enrols patients with obesity-related heart failure with preserved ejection fraction, defined by chronic heart failure symptoms or exertional dyspnea, body mass index at least 30 kg/m2, left ventricular ejection fraction at least 50%, and objective evidence of HFpEF using contemporary diagnostic scores, without a dominant alternative cause of dyspnea. All eligible patients are enrolled regardless of treatment [8].

Calcium-HMB plus vitamin D3 and muscle preservation during semaglutide initiation

A randomised, double-blind, placebo-controlled trial evaluated whether daily calcium beta-hydroxy-beta-methylbutyrate plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes newly starting semaglutide as part of usual care. Participants received the combination or matching placebo for approximately 6 months. The primary outcome was change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6, with secondary assessments of body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate [10].

SYH2069 and glycaemic control in type 2 diabetes

A multicentre, randomised, double-blind, placebo- and active-controlled, dose-finding phase 2 study evaluated SYH2069 injection in participants with type 2 diabetes mellitus inadequately controlled with diet and exercise alone or metformin monotherapy. The study consisted of a 2-week screening period, a 3-week run-in period, a 28-week treatment period, and a 3-week safety follow-up. A total of 240 subjects were stratified by baseline HbA1c and prior metformin use, then randomised to evaluate efficacy, safety, pharmacokinetics, and immunogenicity [12].

Mitochondrial dynamics during Ramadan dry fasting versus 16:8 time-restricted feeding

A study investigated how different types of fasting affect mitochondrial clearance and renewal. While standard intermittent fasting allows water intake, Ramadan dry fasting involves total restriction of both food and fluids from dawn to sunset. The study examined whether the combined effects of fluid restriction and natural daily body rhythms during Ramadan trigger a stronger cellular cleanup process, called mitophagy, compared with standard 16:8 water-permitted fasting, by measuring blood markers related to mitochondrial DNA and metabolic health across a 30-day period [4].

AI-assisted subtyping in acute aortic dissection

A prospective multicentre randomised controlled trial integrated multi-dimensional data to construct an AI immunoinflammatory subtyping system for acute aortic dissection, a condition with acute onset and high mortality in which immunoinflammatory response drives lesion progression. The trial randomised 300 patients to subtyping-based precision therapy or empirical strategies, aiming to establish a subtyping-target-treatment closed loop for emergency needs [1].

GHK and GHK-Cu blood levels after X39 patch application

A two-part clinical trial investigated GHK and GHK-Cu blood levels before and after intervention in healthy adults, and the efficacy of the X39 patch on those levels compared with placebo. The main questions were the change in GHK and GHK-Cu levels from baseline to Day 8, and the difference in that change between the X39 patch and placebo. Participants completed a questionnaire and used the patch [6].

If you are reading this for personal health reasons

The materials described on this page are sold for laboratory research only. We do not provide dosing or medical guidance, and nothing here is a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection — https://clinicaltrials.gov/study/NCT07382375
• [2] Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes — https://clinicaltrials.gov/study/NCT07797036
• [3] Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) — https://clinicaltrials.gov/study/NCT07808333
• [4] Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding — https://clinicaltrials.gov/study/NCT07638696
• [5] Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery — https://clinicaltrials.gov/study/NCT07622992
• [6] Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults — https://clinicaltrials.gov/study/NCT07706361
• [7] Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery — https://clinicaltrials.gov/study/NCT07803250
• [8] GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry — https://clinicaltrials.gov/study/NCT07787936
• [9] Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome — https://clinicaltrials.gov/study/NCT07770282
• [10] HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide — https://clinicaltrials.gov/study/NCT07760948
• [11] The NICE-PAD II Trial — https://clinicaltrials.gov/study/NCT07782671
• [12] A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin — https://clinicaltrials.gov/study/NCT07796477